AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8387966 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline (100 mg twice daily for 14 days)
Number of subjects: 107
Study 3814200 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (10 mg/kg/day)
Number of subjects: 24
Study 3814200 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (2.5‐3 mg/kg/day)
Number of subjects: 24
Study 2752753 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal ring releasing 30 ug/24 hours of 3kDOG (Group A)
Number of subjects: 20
Study 2752753 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal ring releasing 15 ug/24 hours of 3kDOG (Group B)
Number of subjects: 20
Study 2752753 — intervention group
Group type: COMPARATOR
Intervention: Control cycle
Number of subjects: 20
Study 31656130 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralose (8 × 5 g packets/day)
Number of subjects: 38
Study 31656130 — intervention group
Group type: EXPERIMENTAL
Intervention: Steviol glycosides (4 × 1 g packets/day)
Number of subjects: 38
Study 31656130 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose (8 × 5 g packets/day)
Number of subjects: 38
Study 28746153 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic Epidural Analgesia (TEA)
Number of subjects: 140
Study 28746153 — intervention group
Group type: COMPARATOR
Intervention: Intravenous Patient-Controlled Analgesia (IV-PCA)
Number of subjects: 140
Study 28746153 — intervention group
Group type: EXPERIMENTAL
Intervention: TEA
Number of subjects: 140
Study 28746153 — intervention group
Group type: COMPARATOR
Intervention: IV-PCA
Number of subjects: 140
Study 25251249 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality-based rehabilitation combined with conventional occupational therapy (30 mins/session for 9 sessions)
Number of subjects: 40
Study 25251249 — intervention group
Group type: COMPARATOR
Intervention: Conventional occupational therapy (30 mins/session for 15 sessions)
Number of subjects: 40
Study 23732948 — intervention group
Group type: EXPERIMENTAL
Intervention: Random-sequence condition
Number of subjects: 19
Study 23732948 — intervention group
Group type: COMPARATOR
Intervention: Constant-sequence condition
Number of subjects: 19
Study 23732948 — intervention group
Group type: COMPARATOR
Intervention: No-sequence condition
Number of subjects: 19
Study 21282693 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine sterile gloving
Number of subjects: 64
Study 21282693 — intervention group
Group type: COMPARATOR
Intervention: Optional sterile gloving
Number of subjects: 64
Study 19228530 — intervention group
Group type: EXPERIMENTAL
Intervention: E75 peptide vaccine plus granulocyte-macrophage colony-stimulating factor
Number of subjects: 40
Study 19228530 — intervention group
Group type: COMPARATOR
Intervention: Control group (HLA-A2(-) patients)
Number of subjects: 40
Study 19228530 — intervention group
Group type: EXPERIMENTAL
Intervention: E75 peptide vaccine
Number of subjects: 40
Study 19228530 — intervention group
Group type: EXPERIMENTAL
Intervention: E75 peptide vaccine (excluding 3 patients with PSA recurrences during vaccine series)
Number of subjects: 40
Study 16564822 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher humidity range (35% to 45%)
Number of subjects: 0
Study 16564822 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower humidity range (25% to 35%)
Number of subjects: 0
Study 16564822 — intervention group
Group type: COMPARATOR
Intervention: Comparison of evaporative rates between higher and lower humidity
Number of subjects: 0
Study 16564822 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease of 10% RH
Number of subjects: 0
Study 15232762 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective preterm delivery with management plan including high-resolution ultrasound, weekly re-evaluation, corticosteroids, and delivery if bowel compromise present > 30 weeks
Number of subjects: 16
Study 15232762 — intervention group
Group type: COMPARATOR
Intervention: Control group (16 consecutive patients treated prior to management plan)
Number of subjects: 16
Study 11770188 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 48
Study 11770188 — intervention group
Group type: COMPARATOR
Intervention: Continuous combined HRT
Number of subjects: 48
Study 9433369 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine 60 mg twice daily
Number of subjects: 20
Study 9433369 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine 120 mg once daily
Number of subjects: 20
Study 9433369 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg once daily
Number of subjects: 20
Study 9433369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8491949 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (local nasal immunotherapy with macronized powder extract)
Number of subjects: 24
Study 8491949 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 24
Study 3434850 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg) tablets
Number of subjects: 0
Study 3434850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30452918 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic approach (transluminal drainage with or without necrosectomy, n=34)
Number of subjects: 66
Study 30452918 — intervention group
Group type: COMPARATOR
Intervention: Minimally invasive surgery (laparoscopic or video‐assisted retroperitoneal debridement, n=32)
Number of subjects: 66
Study 30452918 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic approach
Number of subjects: 66
Study 30452918 — intervention group
Group type: COMPARATOR
Intervention: Minimally invasive surgery
Number of subjects: 66
Study 27863331 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient enhanced cognitive behavioural therapy for eating disorders (CBT-E)
Number of subjects: 66
Study 26540083 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalfampridine extended release (D-ER) 10 mg twice daily
Number of subjects: 83
Study 26540083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 23410564 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 5145
Study 23410564 — intervention group
Group type: COMPARATOR
Intervention: Diabetes support and education
Number of subjects: 5145
Study 21194006 — intervention group
Group type: COMPARATOR
Intervention: Laser treatment to avascular retina (Group A)
Number of subjects: 50
Study 21194006 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treatment to avascular retina and ridge (Group B)
Number of subjects: 50
Study 21194006 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treatment to ridge (Group B)
Number of subjects: 50
Study 19922017 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg prednisolone daily
Number of subjects: 166
Study 19922017 — intervention group
Group type: COMPARATOR
Intervention: No prednisolone
Number of subjects: 166
Study 16863568 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced magnification endoscopy (EME) directed biopsies targeting mucosal patterns type III or IV.
Number of subjects: 137
Study 16863568 — intervention group
Group type: COMPARATOR
Intervention: Standard endoscopy with random biopsies.
Number of subjects: 137
Study 15242468 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed video
Number of subjects: 1152
Study 15242468 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed pamphlet
Number of subjects: 1152
Study 15242468 — intervention group
Group type: COMPARATOR
Intervention: Usual care/control
Number of subjects: 1152
Study 11283195 — intervention group
Group type: EXPERIMENTAL
Intervention: Fall risk education, home-based exercise programming, nutrition counseling, and environmental hazards education
Number of subjects: 37
Study 11283195 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 37
Study 9416943 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril
Number of subjects: 0
Study 8496536 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 18
Study 8496536 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 18
Study 8496536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 3680538 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program (20 weeks)
Number of subjects: 54
Study 3680538 — intervention group
Group type: COMPARATOR
Intervention: Less vigorous activities (control group)
Number of subjects: 54
Study 31629767 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy food images
Number of subjects: 18
Study 31629767 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperpalatable food images
Number of subjects: 18
Study 31629767 — intervention group
Group type: COMPARATOR
Intervention: Food addiction status
Number of subjects: 18
Study 29378982 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF)
Number of subjects: 30
Study 29378982 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 30
Study 25109606 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 2 mg daily + intensive lifestyle modification (LSM)
Number of subjects: 187
Study 25109606 — intervention group
Group type: COMPARATOR
Intervention: Intensive lifestyle modification (LSM) only
Number of subjects: 187
Study 25109606 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 2 mg daily
Number of subjects: 187
Study 22669010 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco control intervention including health educator visits, discussions led by lead teachers, cessation assistance, posters, and educational materials; implemented over the entire academic year.
Number of subjects: 0
Study 21715141 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive bimanual training (Hand‐Arm Bimanual Intensive Therapy: HABIT)
Number of subjects: 20
Study 21715141 — intervention group
Group type: COMPARATOR
Intervention: Control group (Constraint‐Induced Movement Therapy, CIMT)
Number of subjects: 20
Study 18699750 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery (LS)
Number of subjects: 233
Study 18699750 — intervention group
Group type: COMPARATOR
Intervention: Open surgery (OS)
Number of subjects: 233
Study 16242826 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS
Number of subjects: 27
Study 16242826 — intervention group
Group type: COMPARATOR
Intervention: sham TMS
Number of subjects: 27
Study 14633815 — intervention group
Group type: EXPERIMENTAL
Intervention: Resectional arthroplasty
Number of subjects: 41
Study 14633815 — intervention group
Group type: COMPARATOR
Intervention: Standard nonsurgical care
Number of subjects: 41
Study 10749820 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate loading (9 g CHO/kg body mass/day)
Number of subjects: 7
Study 10749820 — intervention group
Group type: COMPARATOR
Intervention: Placebo-controlled moderate-CHO diet (6 g CHO/kg body mass/day)
Number of subjects: 7
Study 10749820 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate loading
Number of subjects: 7
Study 10749820 — intervention group
Group type: COMPARATOR
Intervention: Placebo-controlled moderate-CHO diet
Number of subjects: 7
Study 9051168 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (3 sessions, one weekly for 3 weeks, stimulating Bladder 10 and Gall Bladder 20 points)
Number of subjects: 15
Study 9051168 — intervention group
Group type: COMPARATOR
Intervention: Control group (17 patients treated with drugs - FANS and myorelaxing - and physiotherapy)
Number of subjects: 15
Study 1627436 — intervention group
Group type: EXPERIMENTAL
Intervention: Single cycle of combination chemotherapy (intravenous cyclophosphamide, methotrexate, and fluorouracil)
Number of subjects: 1275
Study 1627436 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant treatment
Number of subjects: 1275
Study 1627436 — intervention group
Group type: EXPERIMENTAL
Intervention: Single cycle of combination chemotherapy
Number of subjects: 1275
Study 1627436 — intervention group
Group type: EXPERIMENTAL
Intervention: Single cycle of combination chemotherapy (in postmenopausal women with ER-negative tumors)
Number of subjects: 1275
Study 1627436 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant treatment (in postmenopausal women with ER-negative tumors)
Number of subjects: 1275
Study 6392047 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicergoline (Sermion) treatment for one year
Number of subjects: 1366
Study 6392047 — intervention group
Group type: COMPARATOR
Intervention: Placebo (implied control)
Number of subjects: 1366
Study 30782199 — intervention group
Group type: EXPERIMENTAL
Intervention: CC + SI (sustained inflation)
Number of subjects: 0
Study 30782199 — intervention group
Group type: COMPARATOR
Intervention: 3:1 C:V ratio (compression-to-ventilation ratio)
Number of subjects: 0
Study 28624862 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous fibrin glue (AFG)
Number of subjects: 120
Study 28624862 — intervention group
Group type: COMPARATOR
Intervention: Nylon suturing (NS)
Number of subjects: 120
Study 24990421 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX; 8-week intervention)
Number of subjects: 25
Study 24990421 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control (CON)
Number of subjects: 25
Study 23622590 — intervention group
Group type: EXPERIMENTAL
Intervention: ATG tailored according to CD3+ cell count
Number of subjects: 21
Study 23622590 — intervention group
Group type: COMPARATOR
Intervention: ATG according to clinical and total lymphocyte count
Number of subjects: 21
Study 21115860 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus trastuzumab (TH)
Number of subjects: 263
Study 21115860 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel plus carboplatin and trastuzumab (TCH)
Number of subjects: 263
Study 19561519 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine/lamivudine (continue group)
Number of subjects: 234
Study 19561519 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate/emtricitabine (switch group)
Number of subjects: 234
Study 19561519 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 234
Study 17805132 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontic treatment
Number of subjects: 65
Study 17805132 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticotomy‐assisted orthodontic treatment
Number of subjects: 65
Study 17805132 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior segmental osteotomy
Number of subjects: 65
Study 15105223 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg preincisional and 0.2 mg/kg intraoperative S(+)‐ketamine repeated at 20‐min intervals
Number of subjects: 45
Study 15105223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 11378011 — intervention group
Group type: EXPERIMENTAL
Intervention: Talinolol (titrated up to 100 mg/day starting with 12.5 mg daily)
Number of subjects: 294
Study 11378011 — intervention group
Group type: EXPERIMENTAL
Intervention: Talinolol (titrated up to 150 mg/day starting with 12.5 mg daily)
Number of subjects: 294
Study 11378011 — intervention group
Group type: EXPERIMENTAL
Intervention: Talinolol
Number of subjects: 294
Study 11378011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 294
Study 9839638 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy (specifics not provided)
Number of subjects: 0
Study 9839638 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation of individual tumour response to primary medical treatment
Number of subjects: 0
Study 9110909 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline (10 mg a day)
Number of subjects: 341
Study 9110909 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol (2000 IU a day)
Number of subjects: 341
Study 9110909 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (selegiline and alpha-tocopherol)
Number of subjects: 341
Study 9110909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 341
Study 1911319 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terbinafine, 250 mg, once daily for 2 weeks
Number of subjects: 53
Study 1911319 — intervention group
Group type: COMPARATOR
Intervention: Placebo, once daily for 2 weeks
Number of subjects: 53
Study 6286087 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 rad split course (2000 rad in five fractions in one week, two weeks rest and additional 2000 rad in five fractions in one week)
Number of subjects: 378
Study 6286087 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 rad continuous course
Number of subjects: 378
Study 6286087 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 rad continuous course
Number of subjects: 378
Study 6286087 — intervention group
Group type: EXPERIMENTAL
Intervention: 6000 rad continuous course
Number of subjects: 378
Study 6286087 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 rad (split or continuous course)
Number of subjects: 378
Study 6286087 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 to 6000 rad
Number of subjects: 378
Study 6286087 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 rad (for tumors 3 cm or less)
Number of subjects: 378
Study 6286087 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 to 6000 rad (for tumors 3 cm or less)
Number of subjects: 378
Study 6286087 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 rad (for lesions 4 to 6 cm)
Number of subjects: 378
Study 6286087 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 rad (for lesions 4 to 6 cm)
Number of subjects: 378
Study 6286087 — intervention group
Group type: EXPERIMENTAL
Intervention: 6000 rad (for lesions 4 to 6 cm)
Number of subjects: 378
Study 6286087 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 rad
Number of subjects: 378
Study 6286087 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 rad
Number of subjects: 378
Study 6286087 — intervention group
Group type: EXPERIMENTAL
Intervention: 6000 rad
Number of subjects: 378
Study 6286087 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol compliance (irradiated at the primary site according to protocol instruction)
Number of subjects: 378
Study 6286087 — intervention group
Group type: EXPERIMENTAL
Intervention: Major protocol variations in nodal irradiation
Number of subjects: 378
Study 6286087 — intervention group
Group type: EXPERIMENTAL
Intervention: Variations in ipsilateral and contralateral nodal irradiation
Number of subjects: 378
Study 31577867 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive brexpiprazole (1-3 mg/d)
Number of subjects: 3850
Study 31577867 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3850
Study 31577867 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive brexpiprazole (0.5-3 mg/d)
Number of subjects: 3850
Study 31577867 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive brexpiprazole
Number of subjects: 3850
Study 30280635 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy (200 mg of pembrolizumab, carboplatin, and either paclitaxel or nab-paclitaxel)
Number of subjects: 559
Study 30280635 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo plus chemotherapy (saline placebo, carboplatin, and either paclitaxel or nab-paclitaxel)
Number of subjects: 559
Study 30280635 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy
Number of subjects: 559
Study 30280635 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo plus chemotherapy
Number of subjects: 559
Study 26536083 — intervention group
Group type: EXPERIMENTAL
Intervention: High cut-off (HCO) membrane
Number of subjects: 24
Study 26536083 — intervention group
Group type: COMPARATOR
Intervention: High-flux membrane
Number of subjects: 24
Study 25189359 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable polymer sirolimus‐eluting stents
Number of subjects: 2119
Study 25189359 — intervention group
Group type: COMPARATOR
Intervention: Durable polymer everolimus‐eluting stents
Number of subjects: 2119
Study 25189359 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable polymer sirolimus‐eluting stents (in ST-segment elevation myocardial infarction subgroup)
Number of subjects: 2119
Study 25189359 — intervention group
Group type: COMPARATOR
Intervention: Durable polymer everolimus‐eluting stents (in ST-segment elevation myocardial infarction subgroup)
Number of subjects: 2119
Study 22519478 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia (SA)
Number of subjects: 200
Study 22519478 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (GA)
Number of subjects: 200
Study 20142339 — intervention group
Group type: EXPERIMENTAL
Intervention: Strepsils
Number of subjects: 150
Study 20142339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 19223678 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint training group (STG)
Number of subjects: 16
Study 19223678 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordination training group (CTG)
Number of subjects: 16
Study 16159843 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 167
Study 16159843 — intervention group
Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 167
Study 12382295 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee bandage applied
Number of subjects: 20
Study 12382295 — intervention group
Group type: COMPARATOR
Intervention: No bandage applied (Control)
Number of subjects: 20
Study 9763330 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% delmopinol hydrochloride
Number of subjects: 149
Study 9763330 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine digluconate
Number of subjects: 149
Study 7816407 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening primrose oil supplements
Number of subjects: 71
Study 7816407 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 71
Study 7816407 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 71
Study 7816407 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH analogues
Number of subjects: 71
Study 7816407 — intervention group
Group type: EXPERIMENTAL
Intervention: Well-fitting bra
Number of subjects: 71
Study 7816407 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesia
Number of subjects: 71
Study 7816407 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 71
Study 7816407 — intervention group
Group type: EXPERIMENTAL
Intervention: Local excision
Number of subjects: 71